Large Cap · Healthcare · Drug Manufacturers - General
Large Cap · Healthcare · Drug Manufacturers - General
Get the AI take on BIIB
Track it to unlock the price chart, verdict and what could change it.
Free to track. No card required.
Overall score
59/100
See the full financial picture
Open the five-year record, valuation checks and Wall Street view behind these scores.
Free for 3 days, then $9/mo. Cancel anytime.
Lowest
$165
Current price
$218.79
Median target
$238.5
Highest
$300
Forward P/E
Favorable · 28% below avg
15.83x
Price / sales
Reasonable · Priced reasonably against its revenue
3.09x
Price / FCF
Strong · Priced well within what its cash flow supports
11.50x
EV / EBITDA
Strong · Operating earnings comfortably support this price
11.33x
ROIC
Reasonable · A middling return on the capital it puts to work
8.9%
ROE
Needs attention · Unfavorable
4.6%
Debt / equity
Favorable · 0.35 - strong leverage
0.44x
Current ratio
Strong · Comfortable room to cover bills due within a year
1.87x
| Company | Mkt cap | P/E | Rev growth | Score |
|---|---|---|---|---|
| $31.00B | 37.2 | +0.3% | 59 | |
| $11.53B | 22.0 | +19.7% | 78 | |
| $4.60B | 13.9 | +13.5% | 77 | |
| $33.87B | 35.4 | +15.5% | 77 | |
| $1.11T | 40.1 | +49.6% | 76 |